We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Panbela Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $564K → $0 (-$564K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 10

Holders
–
Holders Change
-10
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$449K
2
HF
HRT Financial
New York
-$34K
3
Citadel Advisors
Citadel Advisors
Florida
-$31.3K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$14.5K
5
TRCT
Tower Research Capital (TRC)
New York
-$13.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
HF
1
HRT Financial
New York
– -$34K -1,907 Closed
Citadel Advisors
2
Citadel Advisors
Florida
– -$31.3K -1,711 Closed
Goldman Sachs
3
Goldman Sachs
New York
– -$449K -1,226 Closed
Geode Capital Management
4
Geode Capital Management
Massachusetts
– -$14.5K -794 Closed
TRCT
5
Tower Research Capital (TRC)
New York
– -$13.7K -751 Closed
JP Morgan Chase
6
JP Morgan Chase
New York
– -$11.4K -623 Closed
TSS
7
Two Sigma Securities
New York
– -$10.7K -584 Closed
Osaic Holdings
8
Osaic Holdings
Arizona
– -$63 -4 Closed
Wells Fargo
9
Wells Fargo
California
– -$36 -2 Closed
Morgan Stanley
10
Morgan Stanley
New York
– -$18 -1 Closed
Bank of America
11
Bank of America
North Carolina
– -$2 – –

PBLA Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q1 2024, worth a combined $0 — down 100% from $564K a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of PBLA and 0 opened new positions — a net loss of 10 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Goldman Sachs, exiting entirely with an estimated $449K sold.

  • 0 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q1 2024, down from 10 in Q4 2023.
  • Funds reported $0 of Panbela Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q1 2024 and 10 closed out, a net change of -10 holders.
  • The largest Panbela Therapeutics, Inc. Common Stock seller in Q1 2024 was Goldman Sachs, an estimated $449K sold.

Based on aggregated 13F filings for Q1 2024.